Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about AZN
Recent news which mentions AZN
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
32
33
Next >
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
December 20, 2023
Tickers
AZN
FUSN
NVS
Tags
Trading Ideas
Briefs
FUSN
From
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
Tickers
AZN
BNTX
GSK
JNJ
Tags
JNJ
Market News
Health Care
From
Benzinga
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Tickers
AZN
CGEN
GILD
Tags
Briefs
AZN
News
From
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Tickers
AZN
CGEN
GILD
MARA
Tags
GILD
NASDAQ:CGEN,NASDAQ:GILD,NASDAQ:AZN,NASDAQ:MARA,NASDAQ:MCOM,NASDAQ:PLUG
PLUG
From
InvestorPlace
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
December 18, 2023
Tickers
AZN
LLY
NVO
PFE
Tags
RXRX
PFE
NVO
From
Motley Fool
Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry
December 12, 2023
Tickers
AZN
Tags
News
Market News
Trading Ideas
From
Benzinga
Health Care Company AstraZeneca Announces Acquisition of Icosavax
December 12, 2023
Tickers
AZN
ICVX
Tags
Benzinga
AZN
M&A
From
Benzinga
Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock
December 12, 2023
Tickers
AZN
ICVX
ORCL
Tags
Recent Press Releases
AZN
Market News
From
Motley Fool
Why Is Icosavax (ICVX) Stock Up 46% Today?
December 12, 2023
Tickers
AZN
EBS
ICVX
Tags
Today's Market
AZN
EBS
From
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 12, 2023
Tickers
AAGR
ACHV
AZN
BRSH
Tags
KTTA
AAGR
INAB
From
InvestorPlace
Here’s what hit the Magnificent 7 stocks, and why the selling may continue.
December 12, 2023
Tickers
AAPL
AMC
AMD
AMZN
Tags
T
AMZN
FI:NOKIA
From
MarketWatch
AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M
December 12, 2023
Tickers
AZN
ICVX
Tags
Markets
M&A
Briefs
From
Benzinga
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
December 11, 2023
Tickers
AZN
KTTA
PFE
Tags
PFE
General
News
From
Benzinga
AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease
December 11, 2023
Tickers
AZN
Tags
News
General
Equities
From
Benzinga
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
December 10, 2023
Tickers
AZN
Tags
Market News
AZN
Recent Press Releases
From
Motley Fool
Is Now the Right Time to Buy AstraZeneca Stock?
December 10, 2023
Tickers
AZN
Tags
Market News
AZN
Recent Press Releases
From
Motley Fool
Altimmune’s stock pops as analysts see obesity-drug partnership potential
December 07, 2023
Tickers
ALT
AZN
LLY
NVO
Tags
ALT
AZN
LLY
From
MarketWatch
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
December 07, 2023
Tickers
AZN
BMY
Tags
Health Care
Market News
BMY
From
Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
Tickers
ABSI
AZN
NVDA
RHHBY
Tags
Benzinga
Eurasia
Biotech
From
Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
Tickers
AZN
LLY
NVO
SNY
Tags
Briefs
Large Cap
Markets
From
Benzinga
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
December 01, 2023
Tickers
AZN
Tags
Health Care
Market News
General
From
Benzinga
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
November 27, 2023
Tickers
AZN
Tags
News
Market News
BZI/IA
From
Benzinga
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
November 22, 2023
Tickers
AZN
Tags
Market News
Recent Press Releases
AZN
From
Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
November 22, 2023
Tickers
AZN
DIS
V
Tags
Recent Press Releases
AZN
Market News
From
Motley Fool
5 Growth Stocks to Buy for 2024
November 20, 2023
Tickers
AMD
AMZN
AZN
GOOG
Tags
QCOM
SOFI
AZN
From
InvestorPlace
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
November 17, 2023
Tickers
AZN
SNY
Tags
SNY
Media
Health Care
From
Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
November 17, 2023
Tickers
AZN
NVO
Tags
Market News
AZN
Recent Press Releases
From
Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
Tickers
AZN
GILD
Tags
GILD
Large Cap
Eurasia
From
Benzinga
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
Tickers
AZN
BMY
MRK
RHHBY
Tags
News
General
BMY
From
Benzinga
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
November 14, 2023
Tickers
AZN
Tags
Large Cap
Briefs
AZN
From
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.